Lila PrescottApr 2, 2026 5 min read

How to Access Wegovy's New Subscription Program and Save Up to $1,200

Novo Nordisk announced a new subscription program for Wegovy on March 31, offering self-pay patients lower, predictable monthly pricing on both the injection and the pill. The program is the first of its kind for an FDA-approved GLP-1 weight-loss medication.

Patients who do not have traditional insurance coverage can now choose between three-, six-, or 12-month subscription plans, with longer commitments offering the biggest savings. The 12-month plan saves up to $1,200 a year on the Wegovy injection and up to $600 a year on the pill.

Where to Sign Up

The program launched through three telehealth platforms:

Ro
WeightWatchers
LifeMD

Hims & Hers and Sesame are expected to join soon, with additional telehealth providers to follow. Patients should contact their telehealth provider directly for eligibility and enrollment details, as terms and conditions vary by platform.

Wegovy remains available through more than 70,000 U.S. pharmacies and the NovoCare Pharmacy for those who prefer not to go through a telehealth provider. Patients with commercial insurance can still access Wegovy for as little as $25 per month through existing savings programs.

What It Costs: Wegovy Injection

Current self-pay price without a subscription is $345 per month. Under the new program:

Three-month subscription: $329 per month, saving $240 per year
Six-month subscription: $299 per month, saving $600 per year
12-month subscription: $249 per month, saving $1,200 per year

Patients pay the same monthly price regardless of which injection dose they need — a key detail for those who require higher doses.

What It Costs: Wegovy Pill

Current self-pay price without a subscription is $299 per month. The subscription covers the 9 mg and 25 mg doses. Under the new program:

Three-month subscription: $289 per month, saving $120 per year
Six-month subscription: $269 per month, saving $360 per year
12-month subscription: $249 per month, saving $600 per year

Lower doses of the pill — 1.5 mg and 4 mg — are currently available for $149 per month as a separate limited-time offer. The 4 mg pricing is set to increase to $199 per month after August 31, 2026.

What a Doctor Says

Dr. Jorge Moreno, an obesity specialist at Yale Medicine, said around 20 to 25 percent of his patients already pay for GLP-1 drugs out of pocket because insurance coverage can be unpredictable. He said the new program could help — but comes with caveats.

"This subscription plan could help them if they are able to afford $250 a month, which is still a lot," he said.

Moreno also raised questions about what options patients have if the medication does not work for them, causes significant side effects, or if they simply want to stop during the subscription period. Each telehealth provider sets its own terms around refunds and cancellations, so patients should review those details carefully before enrolling.

Novo Nordisk confirmed that patients can opt out of the subscription while it is still active.

Why Novo Nordisk Is Doing This

Adherence is a known challenge with GLP-1 medications. Physicians report that more than half of their GLP-1 patients stop taking the medication within the first year, with cost being one of the most common reasons.

Novo Nordisk's subscription model is designed to address that directly by locking in predictable pricing over time. The company also faces growing competition in the GLP-1 market, making patient retention and pricing strategy increasingly important.

"The cash prices continue to get more affordable," said Jamey Millar, Novo Nordisk's executive vice president of U.S. operations.

What Wegovy Is and How It Works

Wegovy is the brand name for semaglutide approved specifically for weight loss. It is related to Ozempic, which contains the same active ingredient but is approved for type 2 diabetes management.

Semaglutide mimics a hormone the body produces after eating, which leads to reduced appetite and a feeling of fullness. It is used alongside a reduced-calorie diet and increased physical activity and is FDA-approved to lower the risk of major cardiovascular events — including heart attack and stroke — in adults with obesity who also have known heart disease.